January 2024 Morning Consult Poll about TRIPS Waiver Expansion

First page of a Morning Consult report, commissioned by PhRMA, on the TRIPS Waiver expansion

Morning Consult ran a survey, on behalf of PhRMA, among 1,990 national registered voters focusing on the potential expansion of the TRIPS waiver and the impact that would have on U.S. global leadership, jobs, and pharmaceutical innovation.

First page of a Morning Consult report, commissioned by PhRMA, on the TRIPS Waiver expansion

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.